BOLT BIOTHERAPEUTICS, INC.
-
Open
1.30
-
Previous Close
1.31
-
Volume (Avg)
74.04k (209.48k)
-
Day's Range
1.30-1.35
-
52Wk Range
1.18-3.14
-
Market Cap.
50.47M
-
Dividend Rate ( Yield)
-
-
Beta
-
-
Shares Outstanding
-
-
P/E Ratio (EPS)
-
Top Stories
-
Bolt Biotherapeutics to Present at February Investor Conferences
The Bakersfield Californian 2/1/2023Fireside chat on Thursday, Feb. 16 at 12:40 p.m. PST (3:40 p.m. EST) Live webcasts of the fireside chats will be available on the Events and Presentations page of Bolt’s website at www.boltbio ...
-
Bolt Biotherapeutics, Inc. Common Stock (BOLT)
Nasdaq -
Bolt Biotherapeutics Stock (NASDAQ:BOLT), Guidance and Forecast
Benzinga.com -
Bolt Biotherapeutics Inc
U.S. News & World Report -
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
Benzinga.com 3/14/2023REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics BOLT, a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of ...
-
Bolt Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights
Yahoo -
Bolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conference
Yahoo Finance -
BOLT.OQ - | Stock Price & Latest News | Reuters
Reuters -
Latest Press Releases
Seeking Alpha -
Bolt Biotherapeutics to Present at February Investor Conferences
Yahoo -
Bolt Biotherapeutics Inc.
Wall Street Journal -
Bolt Biotherapeutics, Inc. Common Stock (BOLT)
Nasdaq -
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
Stockhouse -
Bolt Biotherapeutics to Present at February Investor Conferences
MarketWatch -
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
WTEN 3/14/2023REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the ...
-
Bolt Biotherapeutics Inc.
Barron's
